GMAB Stock — Genmab A/S

Genmab A/S (GMAB)

Updated October 16, 2026.

GMAB is a Stock. Total return is 880.9% over the past 17.4 years, 118.1 points behind SPY at 999.0%.

Genmab A/S is a Danish biotechnology company that develops antibody-based products for treating cancer and other diseases, with marketed therapies including EPKINLY and TEPKINLY for lymphomas, Tivdak for cervical cancer, and partnered products like DARZALEX for multiple myeloma and Kesimpta for relapsing multiple sclerosis, alongside a pipeline of candidates in solid tumors and hematologic malignancies. The company does not currently have an established dividend distribution schedule. This security appeals primarily to growth-oriented investors seeking exposure to biopharmaceutical development rather than income investors.

GMAB performance versus SPY

Price and return data through 2026-10-16.

Total return is 880.9% over the past 17.4 years, 118.1 points behind SPY at 999.0%. Over the past year its total return — price change plus distributions reinvested — is 13.0%. Its deepest 1-year drawdown was 32.5%.

GMAB key facts

Asset type

Stock

Asset class

Equity

Inception date

06/01/2009

Distribution frequency

None

Last close

$37.00 (as of 2026-10-16)

Market cap

$22,751,393,980

Average volume

2684549.0

Beta

0.645

Payout ratio

0.0%

P/E ratio

28.46

Forward P/E

15.083

EPS

$1.30

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GMAB risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 32.5%.

Who may consider GMAB — and who may not

It is a weaker fit for investors who need monthly cash flow (GMAB does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on GMAB

• All tickers starting with G

Tagged: Healthcare.

Frequently asked questions